Radioimmunotherapy dose estimation in patients with b-cell lymphoma

Medical Physics

Volumn 20, Issue 2, 1993, Pages 579-582

  Badger, C C ^c  

^a Department of Anesthesiology   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c FRED HUTCHINSON CANCER RESEARCH CENTER   (United States)

Author keywords

dosimetry; lymphoma; radioimmunotherapy

Indexed keywords

ANTIBODY; IODINE 131;

ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; DOSIMETRY; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SICKNESS; RADIOIMMUNOTHERAPY;

HUMAN; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027243278     PISSN: 00942405     EISSN: NA     Source Type: Journal    
DOI: 10.1118/1.597052     Document Type: Article

References (43)

1. V. T. DeVita, E. S. Jaffe, P. Mauch, and D. L. Longo, “Lymphocytic lymphomas”; in Cancer Principals and Practice of Oncology, edited by V. T. DeVita, S. Heilman, and S. A. Rosenberg (J. B. Lippincott, Philadelphia, PA 1989), 3rd ed., pp. 1741–1798.
2. S. C. Carabell, J. T. Chaffey, D. S. Rosenthal, W. C. Moloney, and S. Heilman, “Results of total body irradiation in the treatment of advanced non-Hodgkin's lymphomas,”; Cancer 43, 994–1000 (1979).
3. F. Appelbaum, K. Sullivan, C. D. Buckner, R. A. Clift, H. J. Deeg, A. Fefer, R. Hill, J. Mortimer, P. E. Neiman, J. E. Sanders, J. Singger, P. Stewart, R. Storb, and E. D. Thomas, “Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation,”; J. Clin. Oncol. 5, 1340–1347 (1987).
4. C. C. Badger, C. Anasetti, J. Davis, and I. D. Bernstein, “Treatment of malignancy with unmodified antibody,”; Pathol. Immunopathol. 6, 419–434 (1987).
5. M. E. Kirch and U. Hammerling, “Immunotherapy of murine leuke-mias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells,”; J. Immunol. 127, 805–810 (1981).
6. W. W. Young and S. I. Hakomori, “Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: Selection of low antigenic variants in vivo,”; Science 211, 487-489 (1981).
7. O.W. Press, F. Appelbaum, J. A. Ledbetter, P. J. Martin, J. Zarling, P. Kidd, and E. D. Thomas, “Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas,”; Blood 69, 584–591 (1987).
8. G. Hale, M. J. S. Dyer, M. R. Clark, J. M. Phillips, R. Marcl, L. Riechmann, G. Winter, and H. Waldmann, “Remission induction in non-Hodgkin's lymphoma with a reshaped human monoclonal antibody CAMPATH-1H,”; Lancet 2, 1394–1399 (1988).
9. M. J. S. Dyer, G. Hale, F. G. J. Hayhoe, and H. Waldman, “Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype,”; Blood 73, 1431–1439 (1989).
10. R. A. Miller, R. Maloney, R. Wamke, and R. Levy, “Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody,”; N. Engl. J. Med. 306, 517–522 (1982).
11. T. C. Meeker, J. Lowder, R. G. Maloney, R. A. Miller, K. Thielemans, R. Wamke, and R. Levy, “A clinical trial of anti-idiotype therapy for B-cell malignancy,”; Blood 65, 1349–1363 (1985).
12. H. S. Shin, M. Hayden, S. Langley, N. Kaliss, and M. R. Smith, “Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts,”; J. Immunol. 114, 1255–1263 (1975).
13. R. J. Johnson, R. F. Siliciano, and H. S. Shin, “Suppression of antibody-sensitized cells by macrophages: Insufficient supply or activation of macrophages within large tumors,”; J. Immunol. 122, 379–382 (1979).
14. T. C. Meeker, J. Lowder, M. Cleary, S. Stewart, R. Wamke, J. Sklar, and R. Levy, “Emergence of idiotype variants during treatment of B-cell lymphoma with antiidiotypic antibodies,”; N. Engl. J. Med. 312, 1658–1665 (1985).
15. T. Ghose and A. Guclu, “Cure of a mouse lymphoma with radioiodinated antibody,”; Eur. J. Cancer. 10, 787–792 (1974).
16. C. C. Badger, K. A. Krohn, A. V. Peterson, H. Shulman, and I. D. Bernstein, “Experimental radiotherapy of murine lymphoma with 1311-labeled anti-Thy 1.1 monoclonal antibody,”; Cancer Res. 45, 1536–1544 (1985).
17. O.W. Press, J. F. Eary, C. C. Badger, P.J. Martion, F. R. Appelbaum, R. Levy, R. Miller, S. Brown, W. B. Nelp, K. A. Krohn, D. Fisher, K. DeSantes, B. Porter, P. Kidd, E. D. Thomas, and I. D. Bernstein, “Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody,”; J. Clin. Oncol. 7, 1027–1038 (1989).
18. J. F. Eary, O. W. Press, C. C. Badger, L. D. Durack, K. Y. Richter, S. J. Addison, K. A. Krohn, D. R. Fisher, B. A. Porter, D. L. Williams, P. J. Martin, F. R. Appelbaum, R. Levy, S. L. Brown, R. A. Miller, W. B. Nelp, and I. D. Bernstein, “Imaging and treatment of B-cell lymphoma,”; J. Nucl. Med. 31, 1257–1268 (1990).
19. B. A. Parker, A. B. Vassos, S. E. Halpem, R. A. Miller, H. Hupf, D. G. Amox, J. L. Simoni, R. J. Starr, M. R. Green, and I. Royston, “Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody,”; Cancer Res. 50, 1022s-1028s (1990).
20. C. C. Badger, J. F. Eary, S. Brown, O. Press, J. Davis, F. Appelbaum, W. Nelp, K. Krohn, R. Miller, R. Levy, and I. D. Bernstein, “Therapy of lymphoma with I-131-labeled anti-idiotype antibodies,”; Proc. Am. Assoc. Cancer Res. 28, 388 (1987).
21. S. J. DeNardo, D. L. DeNardo, L. F. O'Grady. N. B. Levy, S. L. Mills, D. J. Macey, J. P. McGahan, C. H. Miller, and A. L. Epstein, “Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using 1–131 Lym-1 monoclonal antibody,”; Antib. Immunoconj. Radiopharm. 1, 17–33 (1988).
22. S. J. DeNardo, G. L. DeNardo, L. F. O'Grady, E. Hu, V. M. Sytsma, S. L. Mills, N. B. Levy, D. J. Macey, C. H. Miller, and A. L. Epstein, “Treatment of B-cell malignancies with 1–131 Lym-1 monoclonal antibodies,”; Int. J. Cancer Suppl. 3, 96–101 (1988).
23. M. S. Kaminski, L. Fig, K. Zasadny, K. Koral, I. Francis, R. Miller, R. L. Wahl, “Phase I evaluation of 131–1 MB-1 antibody radioimmunotherapy (RIT) of B-cell lymphoma,”; Blood 76, 355a (1990).
24. D. M. Goldenberg, R. M. Horowitz, R. M. Sharkey, T. C. Hall, S. Murthy, H. Goldenberg, R. E. Lee, R. Stein, J. A. Siegel, D. O. Izon, B. Burger, L. C. Swayne, E. Belisle, H. J. Hansen, and C. M. Pinsky, “Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody,”; J. Clin. Oncol. 9, 548–564 (1991).
25. S. T. Rosen, A. M. Zimmer, R. Goldman-Leikin, L. I. Gorodon, J. M. Kazikiew, E. H. Kaplan, D. Variakojis, R. J. Marder, M. S. Dykewicz, A. Pierfies, E. A. Silverstein, H. H. Roenigk, and S. M. Spies, “Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using a 1311-labeled monoclonal antibody: An Illinois Cancer Council study,”; J. Clin. Oncol. 5, 562–573 (1987).
26. R. E. Lenhard, S. E. Order, J. J. Spunberg, S. O. Asbell, and A. Leibel, “Isotopic immunoglobin: A new system therapy for advanced Hodgkin's disease,”; J. Clin. Oncol. 3, 1296–1300 (1985).
27. H. M. Vriesendorp, J. M. Herpst, P. K. Leichner, J. L. Klein, and S. E. Order, “Polyclonal yttrium labeled antiferritin for refractory Hodgkin's disease,”; Int. J. Radiat. Oncol. Biol. Phys. 17, 815–821 (1989).
28. H. M. Vriesendorp, S. M. Quadri, R. L. Stinson, O. C. Onyekwere, Y. Shao, J. L. Klein, P. K. Leichner, and J. R. Williams, “Selection of reagents for human radioimmunotherapy,”; Int. J. Radiat. Oncol. Biol. Phys. 22, 37–45 (1992).
29. R. Stein, R. M. Sharkey, and D. M. Goldenberg, “Haematological effects of radioimmunotherapy in cancer patients,”; Br. J. Haematol. 80, 69–76 (1992).
30. S. J. DeNardo, D. L. DeNardo, L. F. O'Grady, N. B. Levy, G. P. Adams, and S. L. Mills, “Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-l,”; Cancer Res. 50, 1014–1016 (1990).
31. D. M. Goldenberg, R. M. Sharkey, S. Murthy, H. J. Hansen, and C. M. Pinsky, “Initial evaluation of repeated low-dose radioimmunotherapy (RAIT) using I-131-LL2 monoclonal antibody (MAb) in patients with lymphoma,”; J. Nucl. Med. 33, 863 (1992).
32. S. B. Sutcliffe, Immunotherapy of the Lymphomas (CRC, Boca Raton, FL, 1985).
33. J. F. Eary, F. R. Appelbaum, L. Durack, and P. Brown, “Preliminary validation of the opposing view method for quantitative gamma camera imaging,”; Med. Phys. 16, 382–387 (1989).
34. R. K. Wu and J. A. Siegel, “Absolute quantitation of radioactivity using the buildup factor,”; Med. Phys. 11, 189-192 (1984).
35. K. F. Koral, K. R. Zasadny, F. M. Swailem, S. F. Buchbinder, I. R. Francis, M. S. Kaminski, and R. L. Wahl, “Importance of intra-therapy single-photon emission tomographic imaging in calculating tumor dosimetry for a lymphoma patient,”; Eur. J. Nucl. Med. 18, 432-435 (1991).
36. G. L. DeNardo, D. J. Macey, S. J. DeNardo, C. G. Zhang, and R. Custer, “Quantitative SPECT of uptake of monoclonal antibodies,”;Semin. Nucl. Med. 19, 22-32 (1989).
37. R. H. J. Begent, J. A. Ledermann, A. J. Green, K. D. Bagshawe, S. J. Riggs, F. Searle, P. A. Keep, T. Adam, R. G. Dale, and M. G. Glaser, “Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer,”; Br. J. Cancer 60, 406-412 (1989).
38. A. Siegel, D. M. Goldenberg, R. M. Sharkey, T. C. Hall, S. Murthy, R. E. Lee, D. A. Pawlak, and L. C. Swaney, “Tumor and organ dosimetry for I-131-labeled LL2 (EPB-2) monoclonal antibody in patients with B-cell lymphomas,”; Antib. Immunoconj. Radiopharm. 4, 649-654 (1991).
39. D. A. Scheinberg, D. J. Strauss, S. D. Yeh, C. Divgi, P. Garin-Chesa, M. Graham, K. Pentlow, D. Coit, H. F. Oettgen, and L. J. Old, “A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression,”; J. Clin. Oncol. 8, 792-803
40. T. E. Hui, D. R. Fisher, O. W. Press, J. F. Eary, J. N. Weinstein, C. C. Badger, and I. D. Bernstein, “Localized beta dosimetry of 1311-labeled antibodies in follicular lymphoma,”; Med. Phys. 9, 97-104 (1992).
41. R. M. Macklis, W. D. Kaplan, J. L. Ferrara, B. M. Kinsey, A. I. Kassis, and S. J. Burakoff, “Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: Implications for radioimmunotherapy,”; Int. J. Ra-diat. Oncol. Biol. Phys. 15, 383-389 (1988).
42. C. C. Badger, J. Davis, C. Nourigat, Z. M. Wu, T. E. Hui, D. R. Fisher, J. Shulman, F. R. Appelbaum, J. F. Eary, K. A. Krohn, D. C. Matthews, and I. D. Bernstein, “Biodistribution and dosimetry following infusion antibodies labeled with large amounts of sup 131I,”; Cancer Res.51, 5921-5928 (1991).
43. K. R. Pollard, A. N. Bice, J. F. Eary, L. D. Durack, and T. K. Lewel-ien, “Imaging therapeutic doses of iodine-131 with a clinical gamma camera,”; J. Nucl. Med. 32, 923 (1991).